Hikma Pharmaceuticals (LON:HIK) was downgraded by investment analysts at Peel Hunt to a “hold” rating in a report released on Monday, November 12th. They presently have a GBX 2,000 ($26.13) price objective on the stock, up from their prior price objective of GBX 1,950 ($25.48). Peel Hunt’s price objective indicates a potential upside of 17.34% from the stock’s previous close.
Several other brokerages have also recently commented on HIK. Citigroup lifted their price objective on shares of Hikma Pharmaceuticals from GBX 2,100 ($27.44) to GBX 2,250 ($29.40) and gave the company a “buy” rating in a research note on Wednesday, October 3rd. Barclays reiterated an “underweight” rating on shares of Hikma Pharmaceuticals in a research note on Monday, October 15th. Numis Securities cut shares of Hikma Pharmaceuticals to a “hold” rating and set a GBX 1,560 ($20.38) target price for the company. in a research note on Thursday, August 9th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and issued a GBX 1,050 ($13.72) target price on shares of Hikma Pharmaceuticals in a research note on Tuesday, August 21st. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Hikma Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of GBX 1,815.71 ($23.73).
LON HIK traded up GBX 17 ($0.22) on Monday, hitting GBX 1,704.50 ($22.27). 410,161 shares of the company’s stock traded hands, compared to its average volume of 822,138. Hikma Pharmaceuticals has a 1-year low of GBX 814.20 ($10.64) and a 1-year high of GBX 2,346 ($30.65).
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Further Reading: When is a capital gain realized?
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.